健胃消痞汤联合雷贝拉唑治疗慢性萎缩性胃炎的临床疗效及对血清G-17、ET-1、胃蛋白酶原、EGF及NO水平的影响

摘要

Objective:To study the clinical efficacy of tonifying stomach and disintegrating lump decoction combined with rabeprazole in the treatment of patients with chronic atrophic gastritis and the effect on the serum G-17,ET-1,PG Ⅰ,PG Ⅱ,EGF and NO levels.Methods:A total of 100 patients with chronic atrophic gastritis in our hospital from June 2015 to March 2017 were enrolled in this study.The subjects were randomly divided into the control group (n=50) and the treatment group (n=50).The control group was treated with rabeprazole,the treatment group was treated with tonifying stomach and disintegrating lump decoction combined with rabeprazole.Both groups were treated for 8 weeks.The clinical effects,changes of serum G-17,ET-1,PG Ⅰ,PG Ⅱ,EGF and NO levels before and after treatment and incidence of adverse reaction rates during treatment were compared between two groups.Results:After treatment,the total efficacy rate of treatment group was 94.00％,which was significantly higher than 78.00％ of the control group (P=0.021).The serum G-17,PG Ⅰ,PG Ⅱ,NO of both groups after treatment were significantly higher than those before treatment (P＜0.05),while the serum ET-1,EGF of both groups after treatment were significantly lower than those before treatment (P＜0.05),and the changes of serum G-17,ET-1,PG Ⅰ,PG Ⅱ,EGF and NO levels of treatment group were significantly better than those of the control group(P＜0.05).There was no significant difference in the adverse reaction rate between two groups during treatment (P=0.461).Conclusion:Tonifying stomach and disintegrating lump decoction combined with rabeprazole had good efficacy and high safety for patients with chronic atrophic gastritis,which might be related to reduce the serum levels ofET-1,EGF and improve the serum levels of G-17,PG Ⅰ,PG Ⅱ,NO.%目的:探讨健胃消痞汤联合雷贝拉唑治疗慢性萎缩性胃炎(chronic atrophic gastritis,CAG)的临床疗效及对血清胃泌素-17(G-17)、内皮素-1 (endothelin-1,ET-1)、胃蛋白酶原、表皮生长因子(EGF)及一氧化氮(NO)水平的影响.方法:选择2015年6月到2017年3月我院收治的100例CAG患者,随机分为对照组和治疗组,每组各50例.对照组患者给予雷贝拉唑治疗,治疗组患者在对照组治疗的基础上联合健胃消痞汤治疗,两组患者均治疗8周.评价并比较两组患者的临床疗效、治疗前后血清G-17、ET-1、胃蛋白酶原Ⅰ(PGⅠ)、胃蛋白酶原Ⅱ(PG Ⅱ)、EGF及NO水平的变化及治疗期间不良反应的发生情况.结果:治疗后,治疗组患者的总有效率为94.00％,明显高于对照组(78.00％)(P=0.021);两组患者血清G-17、PGⅠ、PG Ⅱ及NO水平均较治疗前明显升高,血清ET-1和EGF水平均明显下降,且治疗组以上指标的改善情况均显著优于对照组(P＜0.05).两组患者治疗期间不良反应的发生率比较差异无统计学意义(P=0.461).结论:健胃消痞汤联合雷贝拉唑治疗CAG的临床疗效显著,且安全性较高,可能与其明显改善患者血清G-17、ET-1、PG Ⅰ、PG Ⅱ、EGF及NO水平有关.